BioCentury | Jul 13, 2017
Company News

ASCO recommends MammaPrint to inform chemo use

...cancer in the adjuvant setting, the American Society of Clinical Oncology recommended use of the MammaPrint...
...women who need chemotherapy and those who do not. Agendia N.V. (Amsterdam, the Netherlands) markets MammaPrint...
...the update followed results from the Phase III MINDACT trial, which evaluated the use of MammaPrint...
BioCentury | Jul 10, 2017
Company News

ASCO recommends MammaPrint to inform chemo use

...cancer in the adjuvant setting, the American Society of Clinical Oncology recommended use of the MammaPrint...
...women who need chemotherapy and those who do not. Agendia N.V. (Amsterdam, the Netherlands) markets MammaPrint...
...the update followed results from the Phase III MINDACT trial, which evaluated the use of MammaPrint...
BioCentury | Sep 5, 2016
Clinical News

MammaPrint: Phase III data

...Agendia N.V. , Amsterdam, the Netherlands Product: MammaPrint Business: Diagnostic Molecular target: Not applicable Description: Breast...
...and disease-free survival (DFS); proportion of patients treated with chemotherapy based on clinical prognosis vs. MammaPrint...
...that 46% of patients who were classified as “low risk” for breast cancer recurrence by MammaPrint...
BioCentury | Mar 25, 2015
Politics & Policy

CMS to emphasize clinical utility of prognostic cancer tests

...promoter methylation in patients with colorectal cancer. The committee also considered breast cancer tests including MammaPrint...
BioCentury | Mar 9, 2015
Clinical News

MammaPrint FFPE regulatory update

...FDA granted 510(k) clearance to Agendia’s MammaPrint FFPE test to predict the risk of breast cancer...
...test to predict the risk of breast cancer recurrence in formalin-fixed paraffin embedded (FFPE) tissue. MammaPrint...
...Agendia markets MammaPrint Fresh for fresh tumor tissue. Agendia N.V. , Amsterdam, the Netherlands Product: MammaPrint...
BioCentury | Jan 27, 2015
Politics & Policy

CMS to discuss prognostic tests for cancer

...protein Mlh1 ( MLH1 ) promoter methylation. The committee will discuss breast cancer tests including MammaPrint...
BioCentury | Apr 28, 2014
Product Development

Not so negative

...cancer based on combinations of HER2 mutation and hormone receptor status, and MammaPrint score. The MammaPrint...
...direction, he said. One is an experimental subset of HER2-negative patients characterized as having "ultra-high" MammaPrint...
...of 46.9% compared to 31.7% for the control arm. Berry noted that a distinction between MammaPrint...
BioCentury | Apr 14, 2014
Clinical News

Oral neratinib: Additional Phase II data

...I-SPY 2 were also stratified as "high" or "ultra-high" risk for recurrence based on their MammaPrint...
...neratinib-containing regimen led to an estimated pCR rate of 46.9% vs. 31.7% for standard therapy. MammaPrint...
BioCentury | Feb 3, 2014
Product Development

Spies graduate

...groups based on risk of recurrence as defined by the MammaPrint test from Agendia B.V. MammaPrint...
...of breast cancer recurrence with scores of low, high and MammaPrint ultra high. Patients with MammaPrint...
...were based on but not identical to the enrollment subgroups: HR+, HER2+, HR+/HER2-, HR-, HER2-, MammaPrint...
BioCentury | Nov 27, 2013
Top Story

AHRQ: no evidence of clinical utility for genetic cancer tests

...In a draft technology Oncotype DX breast cancer assay from Genomic Health Inc. (NASDAQ:GHDX) and MammaPrint...
...on downstream outcomes." The agency said there was insufficient evidence to evaluate the impact of MammaPrint...
Items per page:
1 - 10 of 62